Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
PRNewswire - November 21, 2005
SILVER SPRINGS, Md., Nov. 21 /PRNewswire/ -- Zeda Rosenberg, Sc.D., Chief Executive Officer of the International Partnership for Microbicides (IPM), issued the following statement upon reviewing the 2005 AIDS Epidemic Update:
"The UNAIDS report shows that women continue to be disproportionately impacted by HIV. Globally, 17.5 million women are living with HIV -- one million more than in 2003. In several southern African countries, more than three-quarters of all young people living with HIV are women; in sub-Saharan Africa overall, young women between 15 and 24 years old are at least three times more likely to be HIV-positive than young men.
In many countries, the report says, marriage and women's own fidelity are not enough to protect them against HIV infection. In a case study cited in the report, among young women surveyed in Harare (Zimbabwe), Durban and Soweto (South Africa), 66 percent reported having one lifetime partner, and 79 percent had abstained from sex at least until the age of 17. Yet, 40 percent of the young women were HIV-positive. Many had been infected despite staying faithful to one partner.
New prevention strategies such as microbicides are desperately needed by the world's women. Microbicides are products that could be applied topically to the vagina to reduce the transmission of HIV during sexual intercourse. Microbicides could take the form of a gel, cream, film, suppository, sponge or vaginal ring that releases the active ingredient gradually or a new formulation or delivery method yet to be invented.
Recent agreements between IPM and major pharmaceutical companies, which have agreed to give to IPM royalty-free licenses for some of their antiviral drugs for development as microbicides, are exactly what are needed to get microbicides into the hands of women who need them as fast as possible. I hope that other drug companies will soon follow their lead by giving IPM more compounds and new technologies.
According to the new UNAIDS report, the number of people living with HIV has increased in all but one region in the past two years. Sub-Saharan Africa remains the hardest-hit and is home to 25.8 million people living with HIV. Growing epidemics are also underway in Eastern Europe, Central Asia and East Asia."
About IPM
The International Partnership for Microbicides was established to accelerate the development and accessibility of vaginal microbicides to prevent the transmission of HIV. By screening compounds, designing optimal formulations, establishing manufacturing capacity, developing trial sites and conducting large scale efficacy trials, the organization works to improve the efficiency of all efforts to develop and deliver safe and effective microbicides as soon as possible. IPM receives funding from the governments of Canada, Denmark, Ireland, the Netherlands, Norway, Sweden, the United Kingdom and the United States, as well as the European Commission, the Rockefeller and Bill & Melinda Gates Foundations, and the World Bank. More information is available at http://www.ipm-microbicides.org.
SOURCE International Partnership for Microbicides
Web Site: http://www.ipm-microbicides.org
051121
PR051145
Copyright © 2005 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .